Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Executive Summary

Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.

Advertisement

Related Content

New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Another Strong Quarter For AbbVie, But How Long Will Good Times Last?
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar
Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
Amgen Biosimilars Game On: Filing Chases AbbVie's Humira
When It Comes To Biosimilar Marketing, Two Roads Diverge
Defender Or Opponent? Amgen Straddles The Biosimilar Line

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel